Company Overview of Cell>Point L.L.C.
Cell>Point L.L.C., a biopharmaceutical company, develops intra-nuclear universal molecular imaging and therapeutic products for the diagnosis, staging, treatment, and post therapy assessment of cancer, cardiovascular diseases, and infectious diseases. The company focuses on developing universal oncology, cardiology, stroke and diabetes molecular imaging agents, and intra-nuclear metallic therapeutics. It offers radiodiagnostic imaging and intra-nuclear therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy. The company also provides 99mTc-EC-G (oncology), a metabolic imaging agent used to diagnose hyper metabolic activity in cancer cells; 99mTc-E...
7120 East Orchard Road
Centennial, CO 80111
Founded in 2001
Key Executives for Cell>Point L.L.C.
Chief Executive Officer, Founding Member, Managing Member and Founder
Founder, Founding Member, Managing Member and Chief Financial Officer
Founder, Managing Partner, Founding Member and Chief Technology Officer
Compensation as of Fiscal Year 2016.
Cell>Point L.L.C. Key Developments
Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia for Cancer and Heart Disease Diagnostic Imaging
Jun 16 16
Cell>Point announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia which was developed for labeling with technetium-99m for SPECT cameras or 68-gallium for PET cameras for imaging in cancer and cardiovascular disease. Oncardia is based on an ethylenedicysteine drug conjugate platform licensed by Cell>Point from The University of Texas M.D. Anderson Cancer Center. The license with UEP provides for Cell>Point to receive an upfront payment, regulatory milestone payments as well as royalties on sales. Cell>Point will be seeking regulatory approval from the China FDA to expand its Phase 3 lung cancer imaging trial to include clinical sites in China. The parties have agreed that when the current cardiovascular study reaches Phase 3, Cell>Point will include China clinical sites as part of the study.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 13, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries